You are here: Home » News-CM » Equities » Market Report
Business Standard

Benchmarks hit fresh highs; pharma stocks in demand

Capital Market 

The domestic equity benchmarks hit fresh intraday high in early afternoon trade. Pharma shares resumed uptrend after a day's breather.

At 12:28 IST, the barometer index, the S&P BSE Sensex, was up 243.97 points or 0.60% at 40,675.57. The Nifty 50 index added 53.55 points or 0.45% at 11,926.60.

In the broader market, the S&P BSE Mid-Cap index gained 0.23% while the S&P BSE Small-Cap index rose 0.26%.

The market breadth was positive. On the BSE, 1210 shares rose and 1165 shares fell. A total of 152 shares were unchanged.

Derivatives:

The NSE's India VIX, a gauge of market's expectation of volatility over the near term, rose 1.47% to 22.14. The Nifty October 2020 futures were trading at 11,924.75, at a discount of 1.85 points compared with the spot at 11,926.60.

The Nifty option chain for 22 October 2020 expiry showed maximum call open interest (OI) of 35.87 lakh contracts at the 12,000 strike price. Maximum put OI of 38.60 lakh contracts was seen at 11,900 strike price.

The Nifty option chain for 29 October 2020 expiry showed maximum Call OI of 24.56 lakh contracts at the 12,500 strike price. Maximum Put OI of 33.56 lakh contracts was seen at 10,500 strike price.

Buzzing Index:

The Nifty Pharma index rose 0.29% to 11,650.85. The index had lost 1.67% yesterday.

Aarti Drugs (up 2.45%), Torrent Pharma (up 1.11%), Alkem Laboratories (up 0.97%), Divi's Labs (up 0.37%) and Dr. Reddy's Labs (up 0.36%) advanced.

Granules India shed 0.70% ahead of its earnings release today.

Cadila Healthcare rose 0.95% to Rs 426.50 after the drug major received final approval from the US drug regulator to market solifenacin succinate tablets. Solifenacin Succinate is a symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Cadila said that the drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 309 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Strides Pharma Science rose 1.06% to Rs 754.40. The company's subsidiary, Strides Pharma Global, Singapore, has received approval for ethacrynic acid tablets USP, 25 mg from the United States Food & Drug Administration (USFDA). The product is a generic version of Edecrin tablets, 25 mg, of Bausch Health Americas, Inc.

Ethacrynic acid is in a class of medications called diuretics ('water pills'). It is used to treat edema (excess fluid held in body tissues) in adults and children caused by medical problems such as cancer, heart, kidney, or liver disease. According to IQVIA MAT August 2020 data, the US market for ethacrynic acid tablets USP, 25 mg is approximately $14 million.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, October 20 2020. 12:29 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU